Study on Using Indocyanine Green for Detecting Residual Disease in Head and Neck Cancer Surgery

2 1 1 1

What is this study about?

This clinical trial is focused on studying a type of cancer known as epidermoid carcinoma, which affects areas like the mouth and throat. The study is exploring the use of a special imaging technique during surgery to help doctors see if any cancer cells are left behind after the main tumor is removed. This technique uses a substance called indocyanine green, which is injected into the body and helps highlight cancer cells when viewed with a special camera that uses near-infrared light.

The purpose of the study is to see how well this imaging method can detect tiny amounts of cancer that might remain after surgery. During the trial, participants will undergo surgery to remove the cancer, and the imaging technique will be used to check the surgical area for any remaining cancer cells. This will help doctors ensure that as much of the cancer as possible is removed during the operation.

Participants in the study may receive either the imaging technique with indocyanine green or a placebo. The study will monitor the effectiveness of the imaging method in identifying cancer cells and will also track any side effects experienced by participants. The goal is to improve surgical outcomes for patients with epidermoid carcinoma by providing surgeons with better tools to ensure all cancerous tissue is removed.

1 joining the study

Upon joining the study, you will be required to sign an informed consent form. This form confirms that you understand the study and agree to participate.

You must be at least 18 years old, have a confirmed diagnosis of epidermoid carcinoma in the oral cavity or oropharynx, and be eligible for surgery with the goal of complete removal of the tumor.

2 pre-operative visit

Before the surgery, a pre-operative visit will be scheduled. During this visit, a pregnancy test will be conducted for women of childbearing potential.

This visit will occur within 14 days before the administration of the study medication.

3 medication administration

You will receive an injection of indocyanine green, a dye used for imaging purposes. This will be administered intravenously as a solution for injection.

The medication is called INFRACYANINE 25 mg/10 mL.

4 surgery and imaging

During the surgery, near-infrared fluorescence imaging will be used to help detect any remaining cancer cells in the tissue that is removed.

This imaging technique aims to ensure that all cancerous tissue is successfully removed.

5 post-operative evaluation

After the surgery, the removed tissue will be examined to confirm the presence or absence of microscopic residual disease.

The effectiveness of the imaging technique will be evaluated based on its ability to detect any remaining cancer cells.

6 follow-up and monitoring

You will be monitored for any adverse events or side effects related to the study medication and procedure.

The study will assess the safety and tolerability of the imaging technique and medication.

Who Can Join the Study?

Must be a male or female who is 18 years of age or older.
Must have an ECOG performance status of 0-2. This is a scale used to assess how a disease affects a patient’s daily living abilities, where 0 means fully active and 2 means capable of all self-care but unable to carry out any work activities.
Must have a histological confirmation of epidermoid carcinoma. This means that a tissue sample has been examined under a microscope to confirm the presence of this type of cancer.
The primary tumor must be located in the oral cavity or oropharynx. The oral cavity includes the mouth, and the oropharynx is the part of the throat at the back of the mouth.
Must have operable disease with the intention of complete resection. This means the cancer can be surgically removed.
For women of childbearing potential, a negative pregnancy test is required within 14 days before the procedure involving the injection of a substance called indocyanine green.
Must have signed an informed consent form. This means the patient understands the study and agrees to participate.
Must be affiliated with a social security plan or a similar plan.
Must be able and willing to comply with study visits and procedures as outlined in the study protocol.

Who Cannot Join the Study?

Patients with a history of epidermoid carcinoma cannot participate. This is a type of cancer that starts in the cells that make up the outer layer of the skin or the lining of some organs.
Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
Patients who are not part of the specified clinical trial groups cannot participate. This means the study is looking for specific types of participants.
Patients who are part of a vulnerable population cannot participate. Vulnerable populations include groups that may need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Institut Gustave Roussy	Villejuif	France

Other Sites

Site Name	City	Country	Status
Institut Jules Bordet	Anderlecht	Belgium

Trial status

Country	Status	Recruitment Start
Belgium	Recruiting	15.12.2020
France	Recruiting	15.12.2020

Trial locations

Investigated drugs:

Indocyanine Green

Indocyanine Green is a special dye used in medical imaging. In this clinical trial, it is used to help doctors see if there are any tiny bits of cancer left in the tissue after surgery for head and neck cancer. The dye is injected into the body, and it lights up under a special camera that uses near-infrared light. This helps the doctors to see the cancerous areas more clearly during the operation, making it easier to ensure that all the cancer is removed.

Investigated diseases:

Head and neck cancer

Epidermoid carcinoma – Epidermoid carcinoma, also known as squamous cell carcinoma, is a type of cancer that begins in the squamous cells, which are flat cells found in the skin and the lining of some organs. It often occurs in areas exposed to sunlight, such as the skin, lips, and mouth, but can also develop in other parts of the body, including the throat and lungs. The disease progresses as the cancerous cells grow uncontrollably, forming a mass or tumor. As it advances, the carcinoma can invade nearby tissues and spread to other parts of the body through the lymphatic system or bloodstream. The progression can lead to symptoms such as persistent sores, lumps, or changes in the skin or mucous membranes. Early detection and monitoring are crucial to managing the disease effectively.

Trial ID:

2022-502737-26-00

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Using Indocyanine Green for Detecting Residual Disease in Head and Neck Cancer Surgery

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?